Normal CK levels don’t rule out muscle disease

Key Takeaways

• This paper is a case report and literature review, not a trial of creatine supplementation.
• Its core finding is that muscular polyarteritis nodosa can be present even when CK and EMG are normal.
• Normal CK does not reliably exclude important muscle pathology in people with persistent symptoms.
• The study is relevant to creatine because CK is often misunderstood as a ‘creatine test’ when it is not.
• Routine creatine use does not mean someone’s muscle symptoms should be dismissed or blamed on supplements without proper assessment.
• For healthy adults, creatine monohydrate remains the most studied form, typically used at 3-5 g/day or with a 5-7 day loading phase of about 20 g/day split into 4 doses.

What the paper actually found

This new publication is not a creatine supplementation study. It is a case report and literature review about muscular polyarteritis nodosa (MPAN), a rare inflammatory vascular disorder affecting muscle, and its headline message is clinically important: a patient can have significant muscle disease even when creatine kinase (CK) and electromyography (EMG) are normal.

That matters because CK is often treated as a quick proxy for whether muscle symptoms are ‘real’, severe, or likely to show up on lab work. This report pushes back on that assumption. In the condition described, the diagnosis was challenging specifically because two tests many clinicians expect to be abnormal in muscle disease were apparently not.

For Creatine Canada readers, the obvious point of confusion is the word creatine in creatine kinase. CK is an enzyme measured in blood as a marker of muscle damage or leakage. It is not the same thing as dietary creatine, and a normal or abnormal CK result does not tell you whether creatine monohydrate is beneficial, harmful, or responsible for symptoms by itself.

The news value of this paper is therefore diagnostic, not performance-related. It is a reminder that muscle complaints deserve careful workup when symptoms are persistent, unusual, asymmetric, or progressive, even if initial blood work looks reassuring.

Why this matters for creatine users who see ‘CK’ on blood tests

The biggest practical value of this paper is helping people avoid a common misunderstanding: CK is not a creatine supplement test. The shared word root leads many gym-goers to assume that taking creatine somehow automatically ‘raises creatine kinase’ or that CK results can tell them whether creatine is safe for them. That is not what CK measures.

CK can rise after hard training, muscle injury, some medications, and a range of medical conditions. It may also stay normal despite meaningful disease, as this case report highlights. So if someone develops one-sided weakness, pain, swelling, or unexplained functional decline, neither a normal CK nor the fact that they use creatine should end the conversation.

• Normal CK does not guarantee healthy muscle.
• High CK does not automatically mean creatine caused a problem.
• Creatine use should be considered part of a full history, but not a shortcut diagnosis.

This is especially relevant because creatine remains one of the most studied sports supplements, with broad safety data in healthy users when taken appropriately, particularly as monohydrate. If you want the basics on evidence-based use, our creatine guides and creatine dosage calculator can help separate supplementation practice from unrelated lab confusion.

In short, this paper is a warning against oversimplifying muscle symptoms, not a warning about creatine itself.

Study design: useful clinical signal, but not evidence about creatine safety

This article should be read for what it is: a case report plus literature review. That design can be valuable for flagging rare presentations and helping clinicians recognise diagnostic traps. It cannot establish how common those presentations are, quantify risk in the general population, or say anything direct about whether creatine supplementation changes those risks.

Case reports sit near the bottom of the evidence hierarchy for causal claims, but they are often where unusual and important clinical lessons first appear. Here, the lesson is straightforward: relying too heavily on CK and EMG may miss rare muscle-limited vasculitic disease.

The limitations are equally straightforward:

• It appears to centre on a single patient, so generalisability is limited.
• The report concerns a rare disorder, not routine exercise-related soreness or common gym complaints.
• It does not test creatine supplementation, dosing, efficacy, or adverse effects.
• Without broader cohort data, it cannot tell us how often normal CK and EMG occur in MPAN.

That means readers should not take this as evidence that blood tests are useless, only that they are incomplete. Nor should they interpret the paper as proof that creatine is involved in inflammatory muscle disease. It is better understood as a cautionary note about diagnostic reasoning.

If you are comparing supplements, keep the distinction clear: product quality and formulation questions belong in resources like our best creatine rankings, creatine brand reviews, and creatine product catalog, not in disease-specific case reports like this one.

How this fits the broader evidence on creatine and muscle health

Placed in context, this paper does not challenge the mainstream evidence base supporting creatine monohydrate’s effectiveness and general safety in healthy populations. The best-known position statements and reviews continue to describe creatine monohydrate as the most studied form, with typical evidence-based protocols of 3-5 g/day for maintenance or a loading phase of about 20 g/day split into 4 doses for 5-7 days.

For readers who want that wider context, see the ISSN position stand and the review on common questions and misconceptions about creatine. Those sources address frequent myths around kidney health, dehydration, cramping, and testing confusion far more directly than this case report does.

What this new paper adds is not a change in supplement guidance, but a refinement in how readers should think about muscle symptoms and lab interpretation. In practice:

• Creatine can be evidence-based and still be irrelevant to a given medical complaint.
• Muscle symptoms after training are common, but asymmetry, progression, or unusual severity deserve medical attention.
• Lab markers are helpful, but they are one part of a clinical picture, not the whole picture.

That distinction matters in sports nutrition journalism. Good reporting does not turn every paper with the word creatine in it into supplement news. Here, the word belongs to CK, and the real lesson is diagnostic caution.

Practical takeaways if you use creatine and develop muscle symptoms

If you take creatine and notice muscle pain, weakness, swelling, or reduced function, the first step is not to assume either that creatine caused it or that a normal CK clears it. The right response depends on the pattern of symptoms.

For routine training-related soreness after a hard session, conservative self-management is usually enough. But medical review becomes more important when symptoms are persistent, one-sided, worsening, or out of proportion to training load.

Helpful practical rules:

1. Tell your clinician exactly what you take. Include creatine dose, form, start date, and any other supplements or medications.
2. Describe training honestly. Heavy eccentric work can affect muscle markers and symptom interpretation.
3. Do not self-diagnose from CK alone. A single normal result does not rule out all pathology.
4. Use evidence-based dosing. For healthy adults, monohydrate at 3-5 g/day is the standard maintenance approach.

This is also where quality matters more than marketing. If you choose to supplement, stick to reputable products rather than exotic forms with less evidence. Our creatine brand reviews and creatine product catalog can help readers vet options, while the creatine dosage calculator offers a simple way to sanity-check intake.

The central point from this paper remains unchanged: unusual muscle symptoms should be investigated on their own merits, not waved away because CK was normal or because someone happens to use creatine.

Bottom line

This new paper reports a clinically important exception: serious muscle disease can exist despite normal CK and normal EMG. That is the actual finding, and it matters because both patients and clinicians may over-rely on those tests when evaluating muscle complaints.

For creatine users, the article’s relevance is mostly about interpretation. Creatine kinase is not creatine supplementation, and this case report does not show that creatine causes MPAN, worsens it, or changes how standard creatine dosing should be used in healthy adults.

The wider evidence base still supports creatine monohydrate as the best-studied form for performance and training adaptation, typically at 3-5 g/day or with a short loading phase of about 20 g/day split into 4 doses for 5-7 days. What this paper adds is a useful safety-of-thinking lesson: symptoms come first, context matters, and normal labs do not always end the diagnostic process.

If you feel well and use creatine appropriately, there is nothing here that should trigger panic. If you have unusual, persistent, or asymmetric muscle symptoms, there is also nothing here that should reassure you falsely just because CK came back normal.

What this paper changes — and what it doesn’t

• 1 case report — This paper is a single-patient clinical report with literature review, not a supplementation trial.
• 2 normal tests in the case — The headline diagnostic challenge was normal CK and normal EMG despite muscle disease.
• 3-5 g/day standard creatine maintenance dose — Mainstream evidence-based maintenance range for creatine monohydrate in healthy adults.
• 20 g/day common loading protocol — Usually split into 4 doses for 5-7 days in mainstream creatine guidance.

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN